ADVERTISEMENT
Alternative Treatment Options for Older Patients With AML
10/23/2019
In a debate at the 2019 Lymphoma & Myeloma Congress, Sangmin Lee, MD, Weill Cornell Medicine and New, New York, NY, argued that venetoclax combined with azacitidine, decitabine, and LDAC, should not be the new standard of care for AML patients aged ≥60 years.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement